Deep Brain Stimulators Market

The global Deep Brain Stimulators Market is valued at USD 1.2 Billion in 2023 and is projected to reach a value of USD 2.5 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 8.5% between 2024 and 2032. The market is driven by rising neurological disorder prevalence, advancements in neurostimulation technology, increasing demand for minimally invasive treatments, and an aging population susceptible to neurodegenerative diseases.

Key Highlights

• In 2023, North America dominated the market with 52.40% market share
• By Application, Parkinson’s Disease is accounted 60.20% market share
• Based on End Use, the Hospitals segment is dominated the market with 52.30% market share
• Miniaturized device designs, AI-driven personalized therapies, expanding applications beyond Parkinson’s to conditions like depression, and increasing adoption of rechargeable and directional DBS systems

Product Overview

The Product Segment is divided into single channel and dual channel. The Dual Channel held the dominant share in 2023, accounting for significant market share of 56.40%.

The dual-channel segment is dominating the market owing to its higher adoption in surgical procedures. Dual-channel represent some of the most secure and efficient tools employed in surgical interventions. The growing adoption of dual channel DBS for the treatment of various neurological disorders, such as dystonia, Parkinson’s disease, Alzheimer’s disease, and epilepsy, is a key factor fueling the segment growth. Moreover, product approvals are propelling the growth of the dual channel stimulators segment. For Instance, In January 2024, Medtronic plc is a global leader in healthcare technology announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain S timulation (DBS) system. The rechargeable neurostimulator is the latest innovation in the Medtronic Percept™ family, which includes the Percept™ PC neurostimulator, BrainSense™ technology†, and SenSight™ directional leads. The Percept™ family is the only sensing-enabled DBS system on the market, allowing the physician to personalize treatment for patients with movement disorders such as Parkinsons disease, essential tremor, and dystonia as well as epilepsy. Over 11 million people in the U.S. are living with movement disorders and approximately 3.4 million with epilepsy.

Application Overview

The Application segment is divided into pain management, Epilepsy, Essential Tremor, Obsessive Compulsive Disorder, Depression, Dystonia, Parkinson’s Disease, and Others. The Parkinson’s Disease held the dominant share in 2023, accounting for significant market share of 60.20%.

Parkinsons is a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia. DBS is primarily used for patients who no longer respond effectively to medication, offering an alternative that can significantly improve quality of life by reducing motor symptoms. For Instance, In August 2024, Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval of Asleep Deep Brain Stimulation (DBS) surgery for people with Parkinson’s and people with essential tremor. Medtronic is the first and only company to receive FDA approval to offer DBS surgery while a patient is asleep (under general anesthesia) or awake.

Regional Overview

In 2023, the North America captured 52.40% of the revenue share.

North America Deep Brain Stimulators market is driven by increasing government funding and initiatives for raising awareness about Parkinson’s disease (PD). Furthermore, the presence of major competitors, the availability of sophisticated healthcare infrastructure, and supportive government initiatives are also responsible for the market growth in this region. For Instance, in September 2024, Abbott announced that initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the companys deep brain stimulation (DBS) system to manage treatment-resistant depression (TRD), a form of major depressive disorder. The U.S. Food and Drug Administration (FDA) granted Abbott Breakthrough Device designation to explore use of DBS for TRD under its Breakthrough Devices Program, which expedites the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions.

US held the largest Deep Brain Stimulators market share and is anticipated to register the highest CAGR during the forecast period. The market is driven by rising prevalence of neurological diseases such as Parkinsons disease (PD), rising awareness about neurological disorders, and growing investments in developing transcranial stimulators. Additionally, Favorable compensate frameworks and growing government support for neurological research further fuel the adoption of DBS procedures in the U.S. market.

In Europe, Deep Brain Stimulators market is experiencing notable growth, driven by increasing awareness of neurological disorders and the rising prevalence of Parkinsons disease, epilepsy, and dystonia across the region. Favorable reimbursement policies, advancements in healthcare infrastructure, and the strong presence of key medical device companies such as Medtronic and Abbott are contributing to market expansion.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Key Trends

• Technological Advancement: The Technological advancement of more sophisticated DBS systems with features like adaptive stimulation, wireless connectivity, and programmable settings is enhancing the precision and effectiveness of treatment
• Growing Applications: Deep brain stimulators are being explored for a wider range of neurological and psychiatric conditions, including Parkinson’s disease, essential tremor, dystonia, obsessive-compulsive disorder (OCD), and depression.
• Growing Aging Populations: The growing aging population, particularly in developed regions, is driving demand for Deep brain stimulators, as age-related neurological disorders like Parkinson’s disease are becoming more prevalent

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Increasing prevalence of Neurological Disorders

The increasing prevalence of neurological disorders is driven by aging populations and changing lifestyles, is creating a significant patient base for Deep brain stimulator therapy. Growing awareness and acceptance of advanced medical treatments among patients and healthcare providers are also driving the growth of the deep brain stimulator. For instance, according to the World Health Organization (WHO), the number of people aged 60 years and older is expected to double from 1 billion in 2020 to 2.1 billion by 2050, leading to a higher incidence of age-related neurological conditions. This growing patient population is creating a pressing need for effective treatment options, with DBS emerging as a viable solution for managing symptoms and improving the quality of life for affected individuals.

High-Cost of Treatment

The high expenses associated with Deep Brain Stimulators systems and their limited availability in developing and underdeveloped countries are expected to hinder the adoption of these systems, which could restrain revenue growth of the market. Furthermore, challenges in administering appropriate dosages in DBS, the time-consuming and trial-and-error nature of programming, and certain circuit disorders that involve long-term neuroplastic changes, leading to improper DBS dosing are other factors, which could hamper revenue growth of the market.

Competitive Landscape

The Deep Brain Stimulators market is characterized by dynamic and evolving environment with several key players and their ongoing advancement. Major Players like Abbott, Medtronic Plc, Boston Scientific Corporation, Aleva Neurotherapeutics S.A., Nexstim, LivaNova PLC, Neuropace Inc, SceneRay Co. Ltd. These companies have established themselves as leaders in the development and manufacturing of DBS systems, benefiting from strong brand recognition and extensive experience in the field. Companies invest heavily in R&D to introduce next-generation devices that offer better performance and patient outcomes.

The key players in the global Deep Brain Stimulators market include - Abbott among others.

Recent Market Developments

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

• In September 2024, Abbott announced it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the companys deep brain stimulation (DBS) system to manage treatment-resistant depression (TRD), a form of major depressive disorder. The U.S. Food and Drug Administration (FDA) granted Abbott Breakthrough Device designation to explore use of DBS for TRD under its Breakthrough Devices Program, which expedites the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions

Boston Scientific Receives FDA Approval for the Next Innovation in Image Guided Programming Software for Deep Brain Stimulation

• In July 2023, Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration (FDA) approval for the Vercise™ Neural Navigator 5 Software, which when used as part of the Vercise Genus™ Deep Brain Stimulation (DBS) Systems, can provide clinicians with simple and actionable data for efficient programming in the treatment of people living with Parkinson’s disease or essential tremor

The global Deep Brain Stimulators market can be categorized as Product, Application, End-Use and Region.